Ocular adverse events associated with aflibercept and faricimab: a population-based pharmacovigilance study - PubMed
5 hours ago
- #pharmacovigilance
- #anti-VEGF
- #ocular-adverse-events
- Study evaluates ocular adverse events (AEs) for aflibercept (2 mg and 8 mg) and faricimab (6 mg) using FAERS database.
- Retrospective pharmacovigilance analysis from Q4 2023 to Q1 2025 with 462 reports for 2 mg aflibercept, 151 for 8 mg aflibercept, and 2,427 for faricimab.
- Common ocular AEs include intraocular injection complications, increased intraocular pressure, endophthalmitis, reduced visual acuity, eye inflammation, uveitis, visual impairment, and blurred vision.
- Faricimab showed lower reporting odds ratio (ROR) for ocular AEs compared to aflibercept, but wider confidence intervals indicate need for continued safety monitoring.
- Limitations include reporting biases and lack of detailed patient/dosing information in FAERS database.